Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 6.5 Contact Hours.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Ignyta, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, and Takeda Oncology.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

5th Annual Miami Lung Cancer Conference®

5th Annual Miami Lung Cancer Conference®


March 10, 2018
THE DIPLOMAT
3555 South Ocean Drive
Hollywood, FL 33019
Phone: (954) 602-6000
Website: thediplomatbeachresort.com

Overview

Optimized care for patients with lung cancer continues to rapidly evolve across treatment modalities, including chemotherapeutic, targeted, and immuno-oncology strategies. Returning for its 5th year, the Miami Lung Cancer Conference®, will bring the latest updates and advances in current and emerging approaches in treating lung cancer. This 1-day meeting will allow participants to engage with the fields’ top thought leaders, delving into realistic and complex cases. Miami Lung attendees will leave this program able to evaluate emerging therapies, solve unmet clinical problems, and clarify best practice, all to personalize care for their patients with lung cancer. This year’s program will once again highlight PER’s world renowned Medical Crossfire® format, fueling an increased learning and understanding for health care professionals. See you in Miami!

What you will learn at Miami Lung!

  • Methods employed by experts to treat patients with advanced NSCLC who present without actionable oncogenic drivers
  • The cutting-edge research on angiogenesis inhibition in lung cancer, and how these therapies can be used to personalize care in your patients
  • The latest therapies in EGFR-positive NSCLC, and updated strategies to address acquired resistance to EGFR TKIs
  • The latest data on the benefits of immunotherapy and how combination therapies can circumvent escape mechanisms
  • Optimized sequence and ALK inhibitor selection across lines of therapy in NSCLC, and how to address your patients’ crucial questions

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Ignyta, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, and Takeda Oncology.

Learning Objectives

At the conclusion of this symposium, you should be better prepared to:

  • Apply testing approaches to inform clinical decision-making for the treatment of advanced NSCLC in multiple lines of care
  • Report key clinical trial findings on the use of immunotherapeutic strategies in locally-advanced and advanced forms of NSCLC
  • Explain the application of chemotherapeutic and targeted approaches to facilitate sequencing in lung cancer care for tumors with or without oncogenic drivers
  • Determine evolving practices concerning the use of liquid biopsies along the disease continuum in the management of advanced NSCLC
  • Integrate methods to determine treatment approaches, monitor responses, and mitigate the impact of treatment-related toxicities for challenging case scenarios typically encountered in lung cancer management

Program Co-Chairs

Heather A. Wakelee, MD
Associate Professor, Medicine (Oncology)
Stanford University Medical Center
Stanford, CA
 
 

Julie Brahmer, MD
Interim Director, Sidney Kimmel Comprehensive Cancer Center
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
30
Filter By